CpG-methylation-based risk score predicts progression in colorectal cancer.
Epigenomics
; 12(7): 605-615, 2020 04.
Article
en En
| MEDLINE
| ID: mdl-32180433
ABSTRACT
Aim:
To identify patients with colorectal cancer (CRC) who are at a truly higher risk of progression, which is key for individualized approaches to precision therapy. Materials &methods:
We developed a predictor associated with progression-free interval (PFI) using The Cancer Genome Atlas CRC methylation data.Results:
The risk score was associated with PFI in the whole cohort (p < 0.001). A nomogram consisting of the risk score and other significant clinical features was generated to predict the 3- and 5-year PFI in the whole set (area under the curve 0.79 and 0.71, respectively).Conclusion:
The risk score based on 23 DNA-methylation sites may serve as the basis for improved prediction of progression in patients with CRC in future clinical practice.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Colorrectales
/
Islas de CpG
/
Metilación de ADN
Tipo de estudio:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Epigenomics
Año:
2020
Tipo del documento:
Article